Breaking News Instant updates and real-time market news.

HOG

Harley-Davidson

, PYPL

PayPal

$39.96

-0.3 (-0.75%)

09:40
11/29/16
11/29
09:40
11/29/16
09:40

Unusually active option classes on open November 29th

Unusual total active option classes on open include: Harley Davidson (HOG), PayPal (PYPL), Market Vectors Oil Services (OIH), Whiting Petroleum (WLL), Las Vegas Sands (LVS), iShares DJ US Real Estate Index Fund (IYR), US Steel (X), Pfizer (PFE), EWW (EWW), and Chesapeake (CHK).

HOG

Harley-Davidson

PYPL

PayPal

$39.96

-0.3 (-0.75%)

OIH

Oil Services Holders Trust

WLL

Whiting Petroleum

LVS

Las Vegas Sands

IYR

DJ US Real Estate Index Fund

X

U.S. Steel

PFE

Pfizer

EWW

iShares MSCI Mexico

CHK

Chesapeake

  • 29

    Nov

  • 04

    Dec

HOG Harley-Davidson

11/15/16
UBSW
11/15/16
NO CHANGE
Target $57
UBSW
Neutral
Harley-Davidson U.S. retail sales just below flat in October, says UBS
UBS analyst Robin Farley said she believes Harley-Davidson's U.S. retail sales at the dealer level in October, which is seasonally the most important month in Q4, were "just below flat." Additionally, she notes that Harley announced a sales promotion that gives rebates of up to $500 per bike to dealers, which she said is the first time she recalls the company using rebates. Farley keeps a Neutral rating and $57 price target on Harley shares.
11/15/16
11/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fortinet (FTNT) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Melissa Gorham saying she is more constructive on Fortinet heading into fiscal 2017 given the stable demand environment, free cash flow generation, easier comps, and more durable renewals. 2. Advance Auto Parts (AAP) upgraded to Strong Buy from Outperform at Raymond James and to Positive from Neutral at Susquehanna following the company's quarterly report. 3. Chevron (CVX) upgraded to Buy from Outperform at CLSA while the firm also upgraded EOG Resources (EOG) to Outperform from Underperform. 4. Harley-Davidson (HOG) upgraded to Sector Perform from Underperform at RBC Capital with analyst Joseph Spak saying that risks to the company's growth have dissipated, partly due to the potential of President-elect Trump's policies to spark increased consumer spending. 5. Cheesecake Factory (CAKE) upgraded to Buy from Hold at Argus with analyst John Staszak saying investors should be attracted to Cheesecake by its dividend hikes, share repurchases, and ability to open new stores while generating consistent comparable sales growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
RBCM
11/15/16
UPGRADE
RBCM
Sector Perform
Harley-Davidson upgraded to Sector Perform from Underperform at RBC Capital
11/15/16
RBCM
11/15/16
UPGRADE
RBCM
Sector Perform
Harley-Davidson upgraded on lower risk, economic outlook at RBC Capital
As noted earlier, RBC Capital upgraded Harley-Davidson to Sector Perform from Underperform. Analyst Joseph Spak says that risks to the company's growth have dissipated, partly due to the potential of President-elect Trump's policies to spark increased consumer spending. The analyst says that Trump's infrastructure plan will create construction jobs, boosting Harley-Davidson's core customers. Target to $57 from $46.
PYPL PayPal
$39.96

-0.3 (-0.75%)

11/15/16
JEFF
11/15/16
NO CHANGE
JEFF
Jefferies sees attractive entry points for Payments stocks
Payments stocks Visa (V), MasterCard (MA), PayPal (PYPL), Global Payments (GPN), Vantiv (VNTV) have been big underperformers since Election Day as investors rotate into core Financials, Jefferies analyst Jason Kupferberg tells investors in a research note. The corrections of up to 10% are not warranted fundamentally, the analyst contends. Kupferberg sees attractive entry points at current levels and highlights PayPal and Visa as his top picks.
10/21/16
10/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Buy from Hold at Wunderlich and to Outperform from Market Perform at William Blair. 2. Reynolds American (RAI) upgraded to Buy from Hold at Berenberg. 3. eBay (EBAY) upgraded to Buy from Long-Term Buy at Hilliard Lyons. 4. BNY Mellon (BK) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl citing improving fundamentals following the company's third quarter results. 5. PayPal (PYPL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying the company reported "solid" third quarter results and should deliver "stable consistent, and robust" growth going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/16
STFL
10/21/16
UPGRADE
STFL
Buy
PayPal upgraded on growth outlook, multiple catalysts at Stifel
As noted earlier, Stifel upgraded PayPal to Buy from Hold. Analyst Scott Devitt says that the company reported "solid" Q3 results and should deliver "stable consistent, and robust" growth going forward. He thinks that the risk facing the company has dropped significantly recently, and he has become more upbeat on its longer term outlook in light of recent events, including its deals with credit card networks. Devitt recommends aggressively buying the stock. Target $49.
10/21/16
BARD
10/21/16
NO CHANGE
Target $48
BARD
Outperform
PayPal medium-term guidance removes overhang, says Baird
Baird analyst Colin Sebastian noted PayPal reported Q3 results largely in-line with Street expectations, which reflected continuing positive trends driven by secular e-commerce growth and increasing market share. The analyst noted PayPal provided updated three-year financial targets that reflect efforts to gain incremental revenues and cost efficiencies to offset margin headwinds. Sebastian reiterated his Outperform rating and $48 price target on PayPal shares.
OIH Oil Services Holders Trust

WLL Whiting Petroleum

10/28/16
SPHN
10/28/16
UPGRADE
SPHN
Overweight
Whiting Petroleum upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Will Green upgraded Whiting Petroleum to Overweight from Equal Weight, saying that the "worst may be behind" for the company.
10/05/16
MZHO
10/05/16
INITIATION
Target $9
MZHO
Neutral
Whiting Petroleum initiated with a Neutral at Mizuho
Mizuho analyst Timothy Rezvan initiated Whiting Petroleum with a Neutral and a $9 price target.
10/10/16
RHCO
10/10/16
NO CHANGE
RHCO
Whiting Petroleum named top pick at SunTrust
SunTrust analyst Neal Dingmann named Whiting Petroleum as his top pick. The analyst says that recent developments at the company should enable its production to remain "at least flat," while the company should get a big boost from recent oil price rises.
10/28/16
RAJA
10/28/16
UPGRADE
Target $16
RAJA
Strong Buy
Whiting Petroleum upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst John Freeman upgraded Whiting Petroleum to Strong Buy and raised its price target to $16 from $14. The analyst said Whiting reported "extremely impressive" Q3 report and now plans to double its Bakken rig count and sees double-digit production growth from current levels in 2017.
LVS Las Vegas Sands

09/14/16
09/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying an attractive free cash flow and dividend yield makes the risk/reward attractive at current levels. 2. Fifth Third (FITB) upgraded to Buy from Neutral at Compass Point. 3. F5 Networks (FFIV) upgraded to Outperform from Perform at Oppenheimer with analyst Ittai Kidron saying the company has several potential drivers that could drive year-over-year product revenue growth back into positive territory in fiscal 2017. 4. Las Vegas Sands (LVS) upgraded to Buy from Hold at Argus with analyst John Staszak saying that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. 5. DeVry (DV) upgraded to Outperform from Market Perform at Barrington with analyst Alexander Paris saying management's near-term goal is stabilizing revenue at DeVry University growing enrollment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
BOFA
10/04/16
UPGRADE
BOFA
Buy
Las Vegas Sands upgraded to Buy from Neutral at BofA/Merrill
11/21/16
BERN
11/21/16
NO CHANGE
BERN
Macau to grow at 8% CAGR 2016-2020, says Bernstein
Bernstein analyst Vitaly Umansky estimates that Macau's gross gaming revenue will grow at an 8% compound annual growth rate from 2016-2020, driven by non-VIP CAGR of about 11% and VIP CAGR of about 3%. The analyst says that the region's high margin mass gambling is strengthening and continues to be supported by catalysts, while VIP has been growing since September. Umansky identifies Melco Crown (MPEL) as the most undervalued stock in his coverage. He says that the company has multiple positive catalysts, and he keeps a $21.50 price target and a Buy rating on the shares. Other stocks with exposure to Macau include Las Vegas Sands (LVS), Wynn Resorts (WYNN), and MGM Resorts (MGM).
10/04/16
BOFA
10/04/16
UPGRADE
Target $63
BOFA
Buy
Las Vegas Sands upgraded on expected estimate revisions at BofA/Merrill
BofA/Merrill analyst Shaun Kelley upgraded Las Vegas Sands to Buy and raised its price target to $63 from $52. The analyst said shares remain fairly under-owned and thinks estimate revisions will move higher due to market momentum, better ROI for Parisian, Cotai infrastructure additions, and optionality from Japan and real estate.
IYR DJ US Real Estate Index Fund

08/22/16
JEFF
08/22/16
NO CHANGE
JEFF
Jefferies ups SMID-cap Technology to Overweight, cuts REITs to Market Weight
Jefferies Equity Strategist Steven DeSanctis said that in terms of its SMID-cap sector strategy the firm is moving to an Overweight on Technology, citing Tech's "very strong" earnings season, reasonable valuations in the group and expectations for the recent M&A trend to continue. Also, the firm is moving Real Estate to Market Weight from Overweight, citing the belief that investors are shifting their preference towards growth and away from yield.
X U.S. Steel

11/29/16
ARGS
11/29/16
DOWNGRADE
ARGS
Hold
U.S. Steel downgraded to Hold from Buy at Argus
11/21/16
11/21/16
DOWNGRADE

Neutral
Follow-up: U.S. Steel downgraded on valuation, slowing auto growth at Rosenblatt
As previously reported, Rosenblatt downgraded U.S. Steel to Neutral from Buy. Analyst Chris Olin said shares appear fairly valued given recent share strength and reduced demand visibility and decelerating automotive growth.
11/21/16
RSBL
11/21/16
DOWNGRADE
RSBL
Neutral
U.S. Steel downgraded to Neutral from Buy at Rosenblatt
11/14/16
11/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lockheed Martin (LMT) upgraded to Buy from Hold at Stifel with analyst Joseph DeNardi saying he is pleased with the company's comments regarding its 2018 free cash flow outlook, and he thinks that it could benefit from increased defense spending in the wake of the election results. 2. Philip Morris (PM) upgraded to Buy from Outperform at CLSA with analyst Michael Levy citing the recent pullback for his rating change and said he sees the company adding to its buyback. 3. Citi (C) upgraded to Overweight from Equal Weight at Morgan Stanley with analysts led by Betsy Graseck saying the Republican sweep is positive for all financial stocks due to increased growth, higher rates, lower taxes, and less regulation. 4. U.S. Steel (X) and AK Steel (AKS) upgraded to Overweight from Equal Weight at Morgan Stanley. 5. L Brands (LB), Kohl's (KSS), and Chico's(CHS) were upgraded to Buy from Neutral at Citi, while Chico's was also upgraded to Outperform from Peer Perform at Wolfe Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer

11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
LEHM
11/29/16
UPGRADE
Target $38
LEHM
Overweight
Pfizer upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Pfizer to Overweight and raised its price target to $38 from $37. Meacham sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders.
11/02/16
ARGS
11/02/16
DOWNGRADE
ARGS
Hold
Pfizer downgradedon weaker outlook at Argus
As noted earlier, Argus downgraded Pfizer to Hold from Buy. Analyst Jacob Kilstein cited "recent pipeline setbacks, prospects for increased competition, and management's decision to shelve its business separation plan" as reasons for the downgrade.
11/02/16
LEER
11/02/16
NO CHANGE
LEER
Pfizer boco failure should not spillover to other PCSK9 antibodies, says Leerink
Leerink analyst Geoffrey Porges says that Pfizer's (PFE) announcement that it is discontinuing development of anti-PCSK9 antibody bococizumab is significant and may give investors pause regarding the entire anti-PCSK9 antibody class. However, the analyst notes that composite of views suggests Boco-specific factors led to disappointment and to the program discontinuation. Further, Porges does not believes investors should expect any similar effects in the longer term follow up with Amgen's (AMGN) Repatha or Regeneron (REGN)/Sanofi's (SNY) Praluent.
EWW iShares MSCI Mexico

CHK Chesapeake

10/25/16
RBCM
10/25/16
UPGRADE
RBCM
Sector Perform
Chesapeake upgraded to Sector Perform from Underperform at RBC Capital
10/25/16
RBCM
10/25/16
UPGRADE
RBCM
Sector Perform
Chesapeake upgraded on lower costs, improved margin outlook at RBC Capital
As noted earlier, RBC Capital upgraded Chesapeake to Sector Perform from Underperform. As reasons for the upgrade, analyst Scott Hanold cites what he sees as the company's lower cost structure, improved, longer term margin outlook, and "balance sheet enhancements." He thinks that the company's debt reduction targets "look achievable," while the company's long-term outlook is "compelling." Target to $8 from $7.
11/10/16
JEFF
11/10/16
UPGRADE
Target $5
JEFF
Hold
Chesapeake upgraded to Hold from Underperform at Jefferies
Jefferies analyst Jonathan Wolff upgraded Chesapeake Energy to Hold citing valuation and the company's "firmer financial footing." The analyst keeps a $5 price target for the shares.
10/25/16
10/25/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Outperform from Neutral at Wedbush with analyst James Dix saying he expects the acquisition by AT&T (T) to go through. 2. McCormick (MKC) upgraded to Outperform from Neutral at Credit Suisse with analyst Robert Moskow saying the recent selloff in shares provides an opportunity for investors to capitalize on structural demand growth in the spices and seasonings category. 3. Swift Transportation (SWFT) upgraded to Buy from Neutral at UBS with analyst Thomas Wadewitz saying the company's third quarter results showed "solid execution." 4. Chesapeake (CHK) upgraded to Equal Weight from Underweight at Stephens and to Sector Perform from Underperform at RBC Capital. 5. Agnico Eagle (AEM) upgraded to Outperform from Market Perform at Raymond James with analyst Phil Russo citing the recent pullback in shares and operational performance year-to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FB

Facebook

$155.07

1.67 (1.09%)

19:57
06/25/17
06/25
19:57
06/25/17
19:57
Periodicals
Facebook plans to offer TV-quality content by late summer, WSJ says »

Facebook is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

FRO

Frontline

$5.59

0.08 (1.45%)

, GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

19:50
06/25/17
06/25
19:50
06/25/17
19:50
Periodicals
Frontline abandons plans to buy Gener8, WSJ says »

Frontline (FRO) has…

FRO

Frontline

$5.59

0.08 (1.45%)

GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$84.83

0.4 (0.47%)

18:46
06/25/17
06/25
18:46
06/25/17
18:46
Hot Stocks
Third Point confirms $3.5B stake in Nestle, urges change at company »

In a letter published…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$74.84

-0.68 (-0.90%)

18:23
06/25/17
06/25
18:23
06/25/17
18:23
Periodicals
Wal-Mart initially clamped down on alcohol, swearing at Jet.com, WSJ says »

After Wal-Mart acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

17:55
06/25/17
06/25
17:55
06/25/17
17:55
Periodicals
EU plans EUR1B fine against Google this week, FT reports »

The EU plans to levy a…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NSRGY

Nestle

$84.83

0.4 (0.47%)

17:37
06/25/17
06/25
17:37
06/25/17
17:37
Periodicals
Dan Loeb's Third Point targets Nestle, Bloomberg says »

Nestle is being targeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNG

Cheniere Energy

$47.62

0.34 (0.72%)

17:27
06/25/17
06/25
17:27
06/25/17
17:27
Hot Stocks
Cheniere Energy announces commencement of Korea Gas LNG contract »

Cheniere Energy and Korea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$39.15

0.1 (0.26%)

, VIAB

Viacom

$34.11

-0.01 (-0.03%)

16:20
06/25/17
06/25
16:20
06/25/17
16:20
Hot Stocks
Box Office Battle: Fifth 'Transformers' film ekes out $45M in franchise low »

Viacom's (VIA)…

VIA

Viacom

$39.15

0.1 (0.26%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

TWX

Time Warner

$99.70

0.3 (0.30%)

DIS

Disney

$104.36

0.14 (0.13%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

SNE

Sony

$38.52

0.11 (0.29%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

GSK

GlaxoSmithKline

$44.29

0.13 (0.29%)

14:42
06/25/17
06/25
14:42
06/25/17
14:42
Hot Stocks
GlaxoSmithKline granted Orphan designation for multiple myeloma treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$25.33

-0.13 (-0.51%)

14:40
06/25/17
06/25
14:40
06/25/17
14:40
Hot Stocks
Biohaven granted Orphan designation for Rett syndrome treatment »

The FDA granted Biohaven…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$56.42

-0.075 (-0.13%)

14:37
06/25/17
06/25
14:37
06/25/17
14:37
Hot Stocks
Eisai unit receives Orphan designation for myelomonocytic leukemia treatment »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.25

0.1123 (2.19%)

14:23
06/25/17
06/25
14:23
06/25/17
14:23
Hot Stocks
Partner Communications executes early loan repayments, sees Q2 expense »

Partner Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

14:21
06/25/17
06/25
14:21
06/25/17
14:21
Hot Stocks
RA Pharma: Presentation on complement inhibitors supports continued development »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

VSTM

Verastem

$2.32

-0.06 (-2.52%)

14:17
06/25/17
06/25
14:17
06/25/17
14:17
Hot Stocks
Verastem reports long-term follow up data from 'DYNAMO' study »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 29

    Jun

  • 11

    Jul

BMY

Bristol-Myers

$56.64

-0.69 (-1.20%)

14:09
06/25/17
06/25
14:09
06/25/17
14:09
Hot Stocks
Bristol-Myers reports four-year follow up data from 'ELOQUENT-2' study »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 24

    Sep

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

, CELG

Celgene

$134.31

0.63 (0.47%)

14:05
06/25/17
06/25
14:05
06/25/17
14:05
Hot Stocks
Agios Pharmaceuticals reports new data from Phase 1/2 trial of IDHIFA »

Agios Pharmaceuticals…

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

14:00
06/25/17
06/25
14:00
06/25/17
14:00
Hot Stocks
Agios reports updated Phase 2 data on AG-348, sees 1H18 pivotal program »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOW

Intrawest Resorts

$23.65

0.04 (0.17%)

13:53
06/25/17
06/25
13:53
06/25/17
13:53
Hot Stocks
Intrawest Resorts says Hart-Scott-Rodino merger waiting period expires »

Intrawest Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$169.61

-1.07 (-0.63%)

13:31
06/25/17
06/25
13:31
06/25/17
13:31
Periodicals
Cigna could gain over 15% by end of next year, Barron's says »

The GOP healthcare plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$48.03

0.53 (1.12%)

, NKE

Nike

$52.85

0.45 (0.86%)

13:26
06/25/17
06/25
13:26
06/25/17
13:26
Periodicals
Potential Nike-Amazon deal another negative for Foot Locker, Barron's says »

A potential direct-sale…

FL

Foot Locker

$48.03

0.53 (1.12%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

RHT

Red Hat

$99.42

0.54 (0.55%)

13:15
06/25/17
06/25
13:15
06/25/17
13:15
Periodicals
Red Hat may eke out double-digit returns, Barron's says »

Red Hat investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.07

-0.16 (-0.13%)

, UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

13:01
06/25/17
06/25
13:01
06/25/17
13:01
Periodicals
Alexion, United Therapeutics worth a look, Barron's says »

After the recent jump in…

ALXN

Alexion

$126.07

-0.16 (-0.13%)

UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Oct

AIZ

Assurant

$101.25

0.99 (0.99%)

12:32
06/25/17
06/25
12:32
06/25/17
12:32
Periodicals
Assurant could double as investors reevaluate company, Barron's says »

Assurant is shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$38.64

0.09 (0.23%)

12:27
06/25/17
06/25
12:27
06/25/17
12:27
Periodicals
NCR Corp. could gain 30% in a year, Barron's says »

Shares of NCR Corp. could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/25/17
06/25
04:55
06/25/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.